Last reviewed · How we verify

Prevention of Cardiac Transplant Rejection — Treatment Landscape & Competitive Intelligence

Prevention of Cardiac Transplant Rejection (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Cardiac Transplant Rejection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Mycophenolate MYCOPHENOLIC ACID Novartis Antimetabolite Immunosuppressant Inosine-5'-monophosphate dehydrogenase 2 2004-01-01
Cellcept MYCOPHENOLATE MOFETIL Roche Palo Antimetabolite Immunosuppressant Inosine-5'-monophosphate dehydrogenase 2 1995-01-01
Prograf TACROLIMUS Astellas Pharma Calcineurin Inhibitor Immunosuppressant Interferon gamma 1994-01-01
Sandimmune cyclosporine Novartis AG (originally Sandoz) Calcineurin inhibitor (immunosuppressant) Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2 1983-11-14
Sandimmune Ciclosporin Novartis Calcineurin Inhibitor Immunosuppressant [EPC] Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 1983-01-01
Cyclosporin Cyclosporin Karolinska University Hospital Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2
Mycophenolate Mycophenolate Sanofi Inosine-5'-monophosphate dehydrogenase 1, Inosine-5'-monophosphate dehydrogenase 2, Inosine-5'-monophosphate dehydrogenase (IMPDH)
Neoral Neoral Novartis Pharmaceuticals Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2
ciclosporine ciclosporine Hospices Civils de Lyon Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novartis · 2 drugs in Prevention of Cardiac Transplant Rejection
  2. Hospices Civils de Lyon · 1 drug in Prevention of Cardiac Transplant Rejection
  3. Karolinska University Hospital · 1 drug in Prevention of Cardiac Transplant Rejection
  4. Novartis AG (originally Sandoz) · 1 drug in Prevention of Cardiac Transplant Rejection
  5. Novartis Pharmaceuticals · 1 drug in Prevention of Cardiac Transplant Rejection
  6. Roche Palo · 1 drug in Prevention of Cardiac Transplant Rejection
  7. Astellas Pharma · 1 drug in Prevention of Cardiac Transplant Rejection
  8. Sanofi · 1 drug in Prevention of Cardiac Transplant Rejection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Cardiac Transplant Rejection:

Cite this brief

Drug Landscape (2026). Prevention of Cardiac Transplant Rejection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-cardiac-transplant-rejection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing